Skip to content

Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism.

Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism. National Multicentre Descriptive Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01950975
Acronym
MOSAÏQUE
Enrollment
315
Registered
2013-09-26
Start date
2012-02-20
Completion date
Unknown
Last updated
2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malformations With Skin Manifestations Suggesting Mosaicism

Brief summary

The principal result expected is the discovery of inframicroscopic chromosomal rearrangements in regions of the genome not yet known to be involved, or mutations in known candidate genes; The identification of such a mosaic rearrangement in an affected infant would lead to improved genetic counselling. Indeed, as this mosaicism is a consequence of a genetic event occurring at an early stage of embryogenesis, it would be possible to confirm the sporadic nature of the observed disorder and therefore to predict a very low or even negligible risk of recurrence for the couple concerned. For the affected infant, the risk for his/her own offspring will be assessed according to the nature of the genetic anomaly discovered. For medical practice, investigators hope that this study will lead to a clearer definition of the screening modalities for mosaicism in the disorders concerned. In particular, they hope to determine whether or not it is possible to dispense with a skin biopsy, which is more invasive than a blood sample.

Interventions

BIOLOGICALPeripheral blood samples in EDTA tubes
PROCEDURESkin biopsies

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
37 Weeks to No maximum
Healthy volunteers
No

Inclusion criteria

* Persons who have provided written informed consent * Lower age limit: infant born at more than 37 WA * Sporadic disorder * Patients presenting at least two skin criteria, or one skin criterion and one non-skin criterion * Skin criteria: 1- extensive epidermal or sebaceous naevus, 2- Extensive segmental haemangioma, 3- Flat angioma or extensive complex vascular malformation, 4-Pigmentary disorders with patterns suggesting mosaicism (Blaschko lines) * Non-skin criteria: Cerebral, ocular, cardiac or genito-urinary malformation, asymmetric body, segmental hypertrophy of a limb, spinal dysraphism (only when associated with haemangioma)

Exclusion criteria

* Persons not covered by the national health insurance scheme * Mendelian disorders: CM-AVM syndrome, glomangiomatosis, Cowden or Bannayan syndrome, type 1 neurofibromatosis, incontinentia pigmenti, CHILD syndrome, Happle-type chondrodysplasia punctata * Mendelian mosaic disorders: epidermal or epidermolytic, comedo or dyskeratotic nevus. * Family history of one of these disorders * Suspicion or an autosomal dominant disease * Patient and/or parent under guardianship or ward of court

Design outcomes

Primary

MeasureTime frame
Presence or not of inframicroscopic chromosomal rearrangementsbaselines

Secondary

MeasureTime frame
Rate of detection of a chromosomal anomalybaselines

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026